Forward looking statements Certain statements included in this presentation (this "Presentation") that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United S

DRIVEN BY SCIENCE FOCUSED ON LIFE

January 2022 Exhibit 99.1

Forward looking statements Certain

statements included in this presentation (this "Presentation") that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of

1995. Forward-looking statements are sometimes accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook"

and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Nuvation Bio's business

strategies, cash resources, current and prospective product candidates, the potential therapeutic benefit of Nuvation Bio's product candidates, the expected timing of regulatory filings and clearance and clinical trial dose selection, initiation and

data presentation, as well as the potential for market acceptance of any approved products and the related market opportunity. These statements are based on various assumptions, whether or not identified in this Presentation, and on the current

expectations of the management team of Nuvation Bio and are not predictions of actual performance. Actual events and circumstances, many of which are beyond Nuvation Bio's control, are difficult or impossible to predict and may cause actual

results to differ materially from those anticipated by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the inherent uncertainty associated with pharmaceutical product

development and clinical trials; the risk of unexpected emergence of adverse events or other undesirable side effects; delays in clinical trials due to difficulties or delays in the regulatory process, enrolling subjects or manufacturing or

supplying product for such clinical trials; disruptions to normal business operations relating to the COVID-19 pandemic; the risk that Nuvation Bio will be unable to successfully market or gain market acceptance of its product candidates; the risk

that Nuvation Bio's product candidates may not be beneficial to patients or successfully commercialized; the risk that Nuvation Bio has overestimated the size of the target patient population, their willingness to try new therapies and the

willingness of physicians to prescribe these therapies; and developments in the competitive landscape. The risks and uncertainties facing Nuvation Bio are discussed more fully in its Quarterly Report on Form 10-Q filed with the SEC on November 10,

2021, under the heading "Risk Factors," and other documents that Nuvation Bio has filed or will file with the SEC. There may be additional risks that Nuvation Bio does not presently know, or that Nuvation Bio currently believes are immaterial, that

could also cause actual results to differ from those anticipated by the forward-looking statements. In addition, forward-looking statements reflect Nuvation Bio's expectations, plans or forecasts of future events and views only as of the date of

this Presentation. Nuvation Bio anticipates that subsequent events and developments will cause its assessments to change. However, while Nuvation Bio may elect to update these forward-looking statements at some point in the future, Nuvation Bio

specifically disclaims any obligation to do so.

Recent accomplishments and potential

2022 milestones Recent Accomplishments First patient treated with NUV-422 in high grade glioma (HGG) trial in December 2020 Dose escalation ongoing in Phase 1 study in High Grade Glioma (HGG), breast and prostate cancer IND accepted for advanced

Beast Cancer (aBC) Phase 1b combination study with fulvestrant and NUV-422 IND accepted for metastatic Castration-Resistant Prostate Cancer (mCRPC) Phase 1b combination study with enzalutamide and NUV-422 Fast track designation granted for NUV-422

in HGG Wee1 clinical development candidate, NUV-569, declared Bioavailable Drug-Drug conjugate (DDC) candidate in lead optimization Potential 2022 Milestones Identify Recommended Phase 2 dose (RP2D) for NUV-422: Initiate Phase 2 monotherapy dose

expansion cohorts in recurrent Glioblastoma (rGBM), aBC and mCRPC Initiate combination Phase 1b studies in aBC and mCRPC Present initial data from Phase 1 NUV-422 dose escalation study Acceptance of IND for BETi NUV-868 and treatment of first

patient in NUV-868 Phase 1 study in advanced solid tumors Submit Wee1 IND DDC Clinical Candidate Selection A2A Clinical Candidate Selection

rGBM HR+ aBC mCRPC Dec 2020 First

patient dosed Phase 2 Initiation by Year End 2022 Phase 2 Initiation by Year End 2022 NUV-422 | CDK 2/4/6i

TUMOR GROWTH SIGNALING No

Pharmacological Intervention CDK2 CDK4/6 CDK2 TUMOR GROWTH SIGNALING In Presence of First Generation CDK4/6 CDK2 Drives Resistance to CDK4/6 Inhibitors CDKN2A Deletion or alterations commonly Drive Cancer growth Through CDK2/4/6 CDK4/6 CDK2 CDK4/6

CDK2 Nuv-422 selectively targets CDK2 in addition to CDK4/6 and may prevent or reverse resistance CDK4/6 Inhibitors

1st Generation CDK 4 CDK 6 CDK 2 2 2

10000 4 2 2470 2 10 504 2nd Generation CDK 4 CDK 6 CDK 2 PF-06873600 2 4 0.3 NUV-422 2 1 7 CDK 1 2 73 CDK2/4/6 inhibition that avoids CDK1 may be associated with better efficacy and tolerability DRIVES EFFICACY CAUSES TOXICITY IC50 (nM) METASTATIC

Monotherapy Label Adjuvant Setting X ? NATALEE X X PALLAS X PENELOPE-B monarch-E

Isocitrate dehydrogenase wild-type

glioblastoma (IDHwt) rGBM COHORT 1: Up to 40 pts with measurable disease HR+/Her2- aBC post CDK4/6i COHORT 2: Up to 40 pts with measurable disease COHORT 4: Up to 40 pts with active brain mets mCRPC post Androgen Receptor Therapy (AR) & taxane

COHORT 3: Up to 40 pts with measurable disease or rising PSA NUV-422-02 phase 1/2 monotherapy study PHASE 1 Dose Escalation PRIMARY OBJECTIVE: safety, tolerability, RP2D RP2D PHASE 2 in Multiple Tumor Types PRIMARY OBJECTIVE: efficacy HGG, HR+/HER2-

aBC, and mCRPC Including Surgical Substudy in rGBM, and Dose Backfill* *Dose Backfill will enroll additional pts at cleared dose levels to further evaluate safety and PK Phase 1 Dose Escalation Data By Year End

CDKN2A deletion and CDK2 overexpression

associated with worse survival in primary high-grade gliomas CDKN2A Deletion is Associated With Worse Survival1 CDK2 Expression Is Associated With Lower Overall Patient Survival2 (1) 1Appay et al., 2020 2Wang et al., 2016 CDKN2A -/- with MVP and or

necrosis CDKN2A -/- without MVP and or necrosis CDKN2A wt with MVP and or necrosis CDKN2A wt without MVP and or necrosis

NUV-422 is superior to standard of

care temozolomide in xenograft model of GBM Tumor Volume NUV-422 30 mg/kg PO QD

NUV-422-02 rGBM monotherapy phase

1/2 Phase 1 Dose Escalation Data By Year End PHASE 1 Dose Escalation PRIMARY OBJECTIVE: safety, tolerability, RP2D RP2D HGG, including rGBM Dose Escalation & Dose Backfill IDHwt rGBM CDKN2A known status Up to 40 patients Surgical Substudy: rGBM

PRIMARY OBJECTIVE: PK of NUV-422 in resected tumor tissue Up to 30 patients randomized (2:1) PHASE 2 Dose Expansion PRIMARY OBJECTIVE: efficacy; ORR & DOR

NUV-422 has similarly strong potency

in palbociclib-sensitive and palbociclib-resistant cells Cyclin E predicts resistance to palbociclib NUV-422 inhibits growth of palbociclib-resistant ER+ breast cancer cells with high CDK2/Cyclin E Proliferation Inhibition IC50 (nM) Compound

Palbociclib-sensitive cells Palbociclib-resistant cells Cisplatin 11580 10070 Palbociclib 288 1401 NUV-422 229 325 Cyclin E1 PalboS PalboR CDK2 PalboS PalboR Low CCNE combo arm PFS 14.1m High CCNE combo arm PFS 7.6m 3

NUV-422 shows activity across ER+

breast cancer xenografts ER+ breast cancer xenograft ER+ CDK4/6 inhibitor and fulvestrant resistant patient derived breast cancer xenograft harboring an ESR1 mutation ER+ fulvestrant-resistant patient derived breast cancer xenograft NUV-422 30 mg/kg

NUV-422-02 2L+ aBC monotherapy phase

1/2 5 Phase 1 Dose Escalation Data By Year End PHASE 1 Dose Escalation PRIMARY OBJECTIVE: safety, tolerability, RP2D RP2D HR+/HER2- aBC 2L+ Dose Escalation & Dose Backfill HR+/Her2- aBC post CDK4/6i COHORT 2: Up to 40 pts with measurable disease

HR+/Her2- aBC with Active Brain Mets post CDK4/6i COHORT 4: Up to 40 pts with measurable brain lesion PHASE 2 Dose Expansion PRIMARY OBJECTIVE: efficacy; ORR & DOR

NUV-422-03 phase 1b/2 aBC study

NUV-422 in combination with fulvestrant Phase 1b Safety Run-in HR+/HER2- aBC Primary Endpoint: Safety; RP2cD Randomized Phase 2 HR+/HER2- aBC with prior CDK4/6i Primary Endpoint: ORR Stage 1: 20 pts Stage 1: 20 pts Randomize 2:1:1 Stage 2: ~50 pts

NUV-422 monotherapy Expansion: Up to 100 pts NUV-422 + Fulvestrant Stage 2: Up to 50 pts Fulvestrant monotherapy Post PD may receive NUV-422 + FUL Stage 1: 20 pts Stage 2: Up to 50 pts Simon 2-stage design Phase 1b Initiation Mid-2022 HR+/HER2- aBC

with prior CDK4/6i NUV-422 Dose Escalation + Fulvestrant (SOC Dose) RP2cD RP2cD: Recommended Phase 2 Combination Dose FUL: Fulvestrant

Additional xenograft data suggests

broad potential for NUV-422 in endocrine-independent breast cancer Tumor Volume (mm3) Days Tumor Volume Days ER-Negative/HER2-Positive Breast Cancer Xenograft Vehicle NUV-422 Tucatinib NUV-422 + tucatinib Tumor Volume (mm3) Vehicle NUV-422 Tucatinib

NUV-422 + tucatinib NUV-422 + tucatinib + fulvestrant ER-Positive/HER2-Positive Breast Cancer Xenograft Fulvestrant NUV-422 30 mg/kg PO QD

Advanced prostate cancer is

associated with CDK2 overexpression Role of CDK2/4/6 in mCRPC 1 Brighi et al, 2021; Schiewer et al, 2012 2Yin, et al 2018 3 Jorda et al, 2018]. CDK2 expression increases with progression of prostate cancer and is associated with worse prognosis2

CDK2 can phosphorylate and activate AR3 Overexpression of CDK2 is associated with high probability of recurrence2 Critical role of CDK2 as an escape mechanism for G1/S cell cycle targeting provides rationale for targeting CDK2 in addition to

NUV-422 causes tumor regression in

an enzalutamide-resistant patient derived prostate tumor xenograft Individual animal tumor volume NUV-422 30 mg/kg PO QD

NUV-422 shows activity in a prostate

cancer model resistant to standard of care Prostate cancer ARV-7 xenograft that is resistant to standard of care anti-androgen therapies NUV-422 30 mg/kg PO QD

NUV-422-02 mCRPC monotherapy phase

1/2 Phase 1 Dose Escalation Data By Year End PHASE 1 Dose Escalation PRIMARY OBJECTIVE: safety, tolerability, RP2D RP2D Recurrent/Refractory mCRPC Dose Escalation & Dose Backfill PHASE 2 Dose Expansion PRIMARY OBJECTIVE: efficacy; ORR & DOR;

PSA Decline mCRPC post AR & taxane COHORT 3: Up to 40 pts with measurable disease or rising PSA

NUV-422-04 phase 1b/2 study in

mCRPC: NUV-422 combination with enzalutamide Phase 1b Safety Run-in mCRPC Primary Endpoint: Safety; RP2cD Phase 2 mCRPC: Measurable & Unmeasurable Disease Primary Endpoint: ORR; PSA Response Rate Phase 1b Initiation Mid-2022 mCRPC with prior

abiraterone acetate NUV-422 Dose Escalation + Enzalutamide (SOC Dose) RP2cD RP2cD: Recommended Phase 2 Combination Dose FUL: Fulvestrant Overall Cohort includes Measurable and Unmeasurable mCRPC Overall Cohort NUV-422 RP2cD + Enzalutamide (n=20) If

20-patient assessment provides preliminary evidence of efficacy with favorable benefit/risk after Sponsor/IDMC review Measurable Disease Subcohort Expand to a minimum of 20 patients Overall Cohort Expand to a minimum of 40 patients

NUV-868 | BETi Advanced Solid Tumors

Phase 1 Initiation Mid-2022

BET: Bromodomain and extra-terminal

motif proteins BET are a family of proteins (e.g., BRD4) with two bromodomains (BD1 and BD2)1 BET family of proteins have critical biological functions and are found to be altered in many human cancers2 BET proteins play a critical role in gene

transcription1 To date, BET inhibitors have largely focused on targeting both BD1 and BD2 Non-selective BD1/2-inhibitors in development have been associated with tolerability issues, potentially due to BD1 inhibition3 Several BET inhibitors have

advanced to clinical studies, but development has been limited due to PK, toxicity, or lack of efficacy4 Potential strategies to overcome development challenges include investigating BET inhibitors in combination and developing BET inhibitors with

BD2 selectivity 1Taniguchi, 2016 2 Bechter and Schoffski, 2020 3Faivre et al 2020 4Sun et al, 2021

BET: Bromodomain and extra-terminal

motif proteins BET are a family of proteins with two bromodomains (BD1 and BD2) BET proteins can induce the expression of a number of oncogenes, including MYC - an oncogene that cannot be targeted directly with a drug To date, BET inhibitors

have largely focused on targeting both both domains (BD1 and BD2) Non-selective BD1/2-inhibitors in development have been associated with tolerability issues, potentially due to BD1 inhibition1 NUV-868 is a highly selective BD2 vs BD1 BET inhibitor

Selective BD2 vs BD1 inhibition can potentially improve tolerability but has been difficult to achieve Selective BD2 inhibitors have the potential to block many oncogenes, including c-myc 1. Faivre et al 2020; 2. Various assays used; 3. Internal

Nuvation Bio data; 4. https://ash.confex.com/ash/2020/webprogram/Paper140138.html; 5. .https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474678/; 6. https://www.nature.com/articles/s41388-018-0150-2; 7. 2016-EORTCposter-ZenithEpigenetics.pdf BRD4

Affinity2 BD2 BD1 Selectivity NUV-868 2 2920 1460x ABBV-7443 1.05 340 234x PLX-28534 Modest BD2 selectivity CPI-06103 17 85 5x ABBV-0751 3 11 3.7x MK-8628/OTX-0155 17 26 1.5x BI-8949996 41 5 0.1x ZEN-36947 Non-selective

NUV-868 inhibits tumor growth by

down regulating tumor promoting genes BCL-2 and MYC and up regulating tumor suppressor Hexim-1 Pharmacodynamic Markers AML CDX Tumor Volume AML CDX Tumor Volume Veh NUV-868 Veh NUV-868 Veh NUV-868 Bcl-2 cMyc Hexim-1

High selectivity for BD2 over BD1

significantly reduces the gut toxicity observed with other nonselective BET inhibitors NUV-868 (BD2 Selective) May Avoid GI Toxicity ABBV-075 (Dual BD1 / BD2) Vehicle NUV-868 Treatment of mice for 10 days with BD2 selective compound NUV-868 shows no

evidence of goblet cell loss Vehicle ABBV-075 A non-selective inhibitor (ABBV-075) leads to marked reduction in rat small intestine goblet cells1 1Faivre et al 2020 Nat 578

NUV-868 causes tumor reductions in

an enzalutamide-resistant patient-derived prostate cancer xenograft model Enzalutamide-resistant prostate cancer xenograft NUV-868 20 mg/kg QD

BET inhibitors (BRD4) cause

sensitization of HR-proficient cancers to PARP-inhibitors

Combination of NUV-868 + olaparib

increases double stranded DNA breaks ( H2AX) in an HR-proficient ovarian tumor model NUV-868 20 mg/kg QD

NUV-569 | WEE1i Advanced Solid

Tumors IND Submission by Year End 2022

TUMOR GROWTH REPLICATING DAMAGED DNA